Description
Raltegravir is an antiviral compound that inhibits HIV integrase; it is clinically used to treat HIV infection. In pre-clinical models, raltegravir decreases infection rates by preventing insertion of HIV-1 DNA into the host genome.
Product Info
| Cas No. | 518048-05-0 |
|---|---|
| Purity | ≥99% |
| Formula | C20H21FN6O5 |
| Formula Wt. | 444.42 |
| IUPAC Name | N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-2-(2-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}-2-propanyl)-6-oxo-1,6-dihydro-4-pyrimidinecarboxamide |
| Synonym | MK-0518 |
| Solubility | soluble in water, slightly soluble in methanol, very slightly soluble in ethanol and acetonitrile and insoluble in isopropanol. The solubility of raltegravir increases with increasing pH such that its solubility in water is approx. 71 mg/mL. Its pKa is 6.3 |
| Appearance | White to off white powder |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
References
Taramasso L, Madeddu G, Ricci E, et al. Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals. Biomed Pharmacother. 2015 Feb;69:233-6. PMID: 25661363.
Mouscadet JF, Tchertanov L. Raltegravir: molecular basis of its mechanism of action. Eur J Med Res. 2009 Nov 24;14 Suppl 3:5-16. PMID: 19959411.
Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1;48(7):931-9. PMID: 19231980.